T cell-derived immunotherapies pre-clinical lead Established a robust pipeline for in-vitro cross-reactivity assessment of T cell engagers within healthy cells to ensure the safety of lead candidates during selection.Directed the discovery and validation of immunogenic epitopes within both established and novel tumor antigens, laying the groundwork for subsequent therapeutic development.Skillfully managed and cultivated a high-performing team consisting of two research associates, fostering a collaborative environment conducive to innovation and achievement.Championed cross-functional project meetings, effectively delivering strategic updates to senior leadership, thereby ensuring alignment with organizational goals and objectives.

Spearheaded antigen discovery initiatives, uncovering novel class I restricted epitopes crucial for autoimmune, cancer, and infectious disease research, broadening our understanding of immunogenic targets.Orchestrated the development of a bioinformatic pipeline in collaboration with a Contract Research Organization (CRO), enhancing antigen discovery across multiple tumor indications and streamlining the identification process.Selected and advocated for numerous antigens to be integrated into Repertoire's adoptive cell therapy program, aligning with the company's therapeutic objectives and bolstering its portfolio of potential treatment candidates.Performed T cell expansions against the novel antigens identified to assess immunogenicity and advance antigens for candidate selection.

Cooperatively engineered and validated Repertoire’s cutting-edge DECODE TCR discovery platform, revolutionizing T cell receptor sequencing through the integration of single-cell technologies.Innovatively conceptualized and implemented various molecular biology strategies aimed at sequencing the T cell receptor at the single-cell level, enhancing precision and efficiency in data acquisition.Pioneered the design and execution of capture strategies utilizing custom-made hydrogel beads and 10X Genomics technology to sequence oligo-tagged cell surface proteins in single cells, elevating the platform's versatility and applicability.Facilitated a cross-functional meeting bridging scientists spearheading the discovery efforts with the computational team, fostering collaboration to refine algorithms for the analysis and validation of platform results, ensuring robustness and accuracy.Formulated and executed multicolor flow cytometry assays tailored to characterize immune cell populations sourced from human peripheral blood mononuclear cells (PBMCs), augmenting the platform's capacity for comprehensive immune profiling.

Uncovering the way in which post transcriptional modifications regulate gene expression and contribute to genetic variability between seemingly homogeneous cell populations.Advisor: Dr. Nina Papavasiliou

Investigated on the role of glucocorticoids in the proliferation and self-renewal of BFU-e red cell progenitors.Performed high throughput chromatin immunoprecipitation of the glucocorticoid receptor (GR) in the red cell progenitors CFU-E and BFU-E to identify key targets of the GR throughout development.Created a library of targets for further screening. Principal investigator: Dr. Harvey LodishDirect advisor: Dr. Johan Flygare